N.J. med spas are in crisis. Sudden law change leaves some fighting to survive.

It's not just Botox and IV therapy. The reversal of a COVID rule could upend family and maternal care, mental healthcare ...

Bristol-Myers Squibb: A Dividend Gem With Hidden Upside In 2026

Bristol-Myers Squibb is upgraded to Buy as its growth portfolio now offsets legacy declines, validating a bullish contrarian ...

TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis ...

Detailed price information for Tg Therapeutics (TGTX-Q) from The Globe and Mail including charting and trades.
Everyday Health on MSN

SCIg for primary immunodeficiency: Troubleshooting swelling, redness, and pain at the infusion site

Discover tips for managing swelling, redness, and pain at subcutaneous immunoglobulin (SCIg) infusion sites for primary ...

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple ...

Detailed price information for Tg Therapeutics (TGTX-Q) from The Globe and Mail including charting and trades.

Hospital performs first successful pediatric bone marrow transplant in Central Texas

The recovery process takes months, hence why the hospital’s Tuesday announcement came roughly five months later.
Cochrane

Should we remove peripheral venous catheters ('intravenous drip' or 'cannula') only when they are not needed or have a complication, or should we remove them regularly?

Future research should focus on testing PVC removal beyond 96 hours, patient preferences for routine or clinically indicated PVC removal, more rigorous studies and use of ultrasound to assess PVC ...

Shopper Blog: Three-legged red panda brings inspiring story to Zoo Knoxville

Shopper News brings you the latest happenings in your community ...
TMCnet

FDA Accepts LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under ...

LEQEMBI is currently approved in 53 countries and regions and is under regulatory review in 7 countries. In August 2025, the US FDA approved LEQEMBI IQLIK 360 mg for weekly subcutaneous maintenance ...

Biogen Inc.: FDA Accepts LEQEMBI IQLIK (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's ...

If approved, LEQEMBI IQLIK would be the first and only anti-amyloid treatment to offer at-home injection options for initiation and maintenance dosing for this progressive, relentless disease FDA acti ...

‘Disgusted with myself’: Former Australian tennis pro says blood transfusion led to doping probe

A one-time world No.39, and coach to some of Australia’s top players, says it was reckless to undergo the procedure in Mexico ...